Beckman predicts surge in routine chemistry sales in H2
This article was originally published in Clinica
Executive Summary
Beckman Coulter's immunodiagnostics and hematology units experienced the company's greatest quarterly growth rates, with sales increases of 10% and 11%, respectively. Despite flat growth, president and CEO John Wareham remained optimistic regarding the routine chemistry unit, claiming "sales in routine chemistry should pick up dramatically" in the second half, spurred on by a healthy hospital market and four supply contracts with Premier, worth over $173m over 21 months. Mr Wareham is anticipating full-year sales growth of 6-7% and net earnings to reach the expected 18-20%.